Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1435-1442

  Hsieh, Wen Son ^d   Soo, Ross ^a   Pen, Bee Keow ^b   Loh, Thomas ^d   Dong, Difeng ^c   Son, Donny ^e   Wong, Lim Soon ^c,e   Green, Simon ^f   Chiao, Judy ^f   Cui, Chun Ying ^a   Lai, Yoke Fong ^d   Lee, Soo Chin ^a   Mow, Benjamin ^a   Soong, Richie ^b   Salto Tellez, Manuel ^b   Goh, Boon Cher ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b Oncology Research Institute   (Singapore)

^c School of Computing   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

^f CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN E; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; ROSCOVITINE; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; PURINE DERIVATIVE; VIRUS DNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; NASOPHARYNX CANCER; NECROSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; VOMITING; AGED; BLOOD; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; NASOPHARYNX TUMOR; ORAL DRUG ADMINISTRATION; PATHOLOGY; VIROLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLIN D1; DNA, VIRAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES;

EID: 63149192752     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1748     Document Type: Article

References (28)

1. Shapiro Gi, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 1999;104: 1645-53.
2. 1phase progression. Genes Dev1999;13:1501-12.
3. Bregman DB, Pestell RG, Kidd VJ. Cell cycle regulation and RNA polymerase II. Front Biosci 2000;5: D244-57.
4. Derheimer FA, Chang CW, Ljungman M. Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer 2005;41:2569-76.
5. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase ll-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005:65:5399- 407.
6. Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005;65:7717-23.
7. Whittaker SR, Walton Ml, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
8. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
9. Chen R, Keating MJ, Gandhi V, PlunkettW. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106: 2513-9.
10. Hui AB, OrYY.Takano H, et al. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 2005;65:8125-33.
11. Lo KW, Cheung ST, Leung SF, et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 1996;56:2721 -5.
12. Lo KW, Huang DP, Lau KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 1995:55: 2039-43.
13. Li AA, Ng E, Shi W, et al. Potential efficacy of p16gene therapy for EBV-positive nasopharyngeal carcinoma. Int J Cancer 2004;110:452-8.
14. Benson C, White J, De Bono J, et al. Phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37.
15. Ma BB, King A, LoYM, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:714-20.
16. Chan AT, Ma BB, LoYM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus NA. J Clin Oncol 2004;22:3053-60.
17. LoYM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
18. Alvi AJ, Austen B, Weston VJ, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484-91.
19. Tsao SW, Tramoutanis G, Dawson CW, Lo AK, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:473-87.
20. Dirmeier U, Hoffmann R, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005:24:1711 -7.
21. WatanabeT, Huang HB, Horiuchi A, et al. Protein phosphatase 1 regulation by inhibitors and targeting subunits. Proc Natl Acad Sci U S A 2001;98:3080-5.
22. Effert P, McCoy R, Abdel-Hamid M, et al. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 1992;66:3768-75.
23. Sun Y, Hegamyer G, Cheng YJ, et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A1992;89: 6516-20.
24. Spruck CH, III Tsai YC, Huang DP, et al. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992;52:4787-90.
25. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005;280:19166-76.
26. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluc- tant cells to tumor necrosis factor. Cancer Res 2004; 64:3653-60.
27. Lu W, Chen L, Peng Y, et al. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001:20:3206-16.
28. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7 4209-42.